

MANAGEMENT OF MG: CHALLENGES AND KEY LESSONS

2025.10.14



Hiroyuki Murai, Department of Neurology
International University of Health and Welfare
Narita, Japan

COI Disclosure

Name of Presenter : Hiroyuki Murai


Companies, etc. in a relation of conflict of interest requiring disclosure in relation to the presentation:

①Advisor:	Alexion, argenx, UCB
②Stock ownership/capital gain:	None
③Patent royalties:	None
④Honoraria:	JB, Chugai, Novartis, Janssen
⑤Writing fees:	None
⑥Grants:	Ministry of Health, Labour and Welfare
⑦Scholarship grants:	None
⑧Endowed chair:	None
⑨Other forms of compensation:	None

Today, we will learn about:


- 1 ■ Pathomechanisms of MG
- 2 ■ Avoiding high dose oral steroids
- 3 ■ Treatment goal of MG
- 4 ■ Treatment algorithm for MG
- 5 ■ Molecular targeted drugs for MG

1 ■ Pathomechanisms of MG



Drawn by the presenter

2 ■ Avoiding high dose oral steroids



3 ■ Treatment goal of MG

■ Japanese guidelines

Murai et al. Clin Exp Neuroimmunol. 2015; 6: 21
Murai et al. Clin Exp Neuroimmunol. 2023; 14: 19

MGFA-PIS classification minimal manifestations (MM) or better, with oral prednisolone (PSL) of 5 mg/day or below (MM-5mg)

■ International guidance

Sanders et al. Neurology. 2016; 87: 419


MGFA-PIS classification minimal manifestations (MM) or better, with no more than **grade 1** Common Terminology Criteria for Adverse Events (CTCAE) medication side effects

*CTCAE grade 1:
asymptomatic or only mild symptoms; intervention not indicated.

4 ■ Treatment algorithm for MG (Japan)

Ocular

Generalized



5 ■ Molecular targeted drugs for MG

	Rituximab	Efgartigimod IV	Efgartigimod SC	Rozanolixizumab	Eculizumab	Ravulizumab	Zilucoplan
Classification	B cell inhibitor	FcRn inhibitor	FcRn inhibitor	FcRn inhibitor	C5 inhibitor	C5 inhibitor	C5 inhibitor
Type of MG	N/A	all gMG	all gMG	all gMG	AChR Ab+ gMG	AChR Ab+ gMG	AChR Ab+ gMG
Product	monoclonal antibody	Fc fragment	Fc fragment/hyaluronidase	monoclonal antibody	monoclonal antibody	monoclonal antibody	peptide
Route	IV	IV	SC	SC	IV	IV	SC
Time	several hrs	60 min	30-90 sec	30-60 sec	30-40 min	30-60 min	5 sec
Frequency	Q6M (2-4 consecutive weeks)	4 consecutive weeks	4 consecutive weeks	6 consecutive weeks	Q2W	Q8W	everyday
Home administration	No	No	Yes	No	No	No	Yes
Mechanism	Block CD20	Block IgG recycling	Block IgG recycling	Block IgG recycling	Block C5 cleavage	Block C5 cleavage	Block C5 cleavage and binding of C5b and C6